



York Health Economics Consortium

Providing consultancy and research in health economics for the NHS, pharmaceutical and health care industries since 1986

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Physical Activity and the Environment

Final Report

JAMES LOVE-KOH, Research Consultant
MATTHEW TAYLOR, Director

03 August 2017

Contents

Page No.

Acknowledgements

Section 1: Introduction	4
1.1 Background	4
1.2 Objectives	5
Section 2: Methods	6
2.1 Model Overview	6
2.2 Model Structure	7
2.3 Model Inputs	8
Section 3: Results	26
3.1 Scenario Analysis	26
3.2 Case Study Results	31
3.3 Sensitivity Analysis	41
Section 4: Discussion	46
References	49

All reasonable precautions have been taken by YHEC to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall YHEC be liable for damages arising from its use.

Acknowledgements

The authors would like to thank the Public Health Advisory Committee (PHAC) for their comments and suggestions.

Abbreviations

1
2
3
4

CHD	Coronary heart disease
CPA	Compendium of Physical Activity
HRQOL	Health-related quality of life
HSE	Health Survey for England
ICER	Incremental cost-effectiveness ratio
MET	Metabolic equivalent time
ONS	Office for National Statistics
NHS	National Health Service
NICE	National Institute for Health and Care Excellence
NHB	Net health benefit
PSS	Personal Social Services
PSSRU	Personal Social Services Research Unit
QALY	Quality-adjusted life year
RR	Relative risks
WIAT	Woods In and Around Towns
WHO	World Health Organization

5
6

Plain Language Summary

In order to help the Public Health Advisory Committee (PHAC) to develop recommendations for the guidance on physical activity and the environment, we developed a cost-effectiveness model. The model was developed so that we could use the best-available information in order to understand how different interventions might affect the health of the general population, as well as the impact that the intervention might have on the costs to the National Health Service (NHS), local authorities and to society as a whole.

We used national health survey data to estimate the current level of physical activity in the UK population, and how these levels changed after an intervention was introduced. We also used information from other studies to estimate how the risk of developing five health conditions changed depending on physical activity level. The conditions we included were breast and colon cancer, diabetes, stroke and coronary heart disease. As we also know the costs associated with each of these complications, it was possible to calculate the overall costs for each group of people over their remaining lifetimes.

As well as estimating costs, we measured the health benefits that people would gain by increasing their physical activity. This was done by combining the increases in life expectancy with the increases in individual quality of life (by avoiding some of the conditions listed above). This allowed us to calculate a measure known as the *quality-adjusted life year* gain for a person that could potentially be achieved by increasing weekly physical activity.

For each intervention that we assessed, the health benefits were matched against the costs that would be incurred to deliver it. This was not an easy task, as many environmental interventions, such as installing cycle lanes or renovating parks, vary substantially from place to place. Due to this variability in costs, we calculated the maximum cost per person that each intervention could be in order for the benefits to outweigh the costs.

The results of the analysis showed that interventions could be cost effective if modest numbers of people increased their physical activity. If we consider a town with a population of 100,000 people, then an intervention that cost £10 per person would be beneficial to fund it if it motivated 1,000 people to cycle for an additional 30 minutes per week or 1,900 people to walk an extra 30 minutes per week. If the intervention cost £100 per person, a greater amount of additional physical activity would be required in order for it to be worthwhile: the equivalent of 5,100 people cycling an additional 30 minutes per week or 11,000 walking an additional 30 minutes per week.

When we looked at specific schemes previously undertaken in the UK that amended transport infrastructure, increased public transport and changed open spaces, we found the benefits outweighed the costs even up to costs of £100 per person. An intervention that completely renovated a local greenway, regenerated park land and added cycle and walking paths was even better and would be cost-effective up to an intervention cost of £190 per person. Studies looking at renovation and infrastructure projects from the USA further supported these

53 conclusions: the physical activity improvements were so great for these interventions that a
54 cost of over £500 per person was justified. However, one study looking specifically at park
55 renovations (such as new fitness equipment and play areas) was not very cost-effective and
56 would only be funded if the costs were less than £20 per person.

57

58 Our results did not substantially change when we changed parts of the model. For example,
59 we looked at what would happen if people did not sustain the activity improvements they
60 experienced from the intervention. We are therefore confident that our results are informative
61 in determining the value of environmental interventions to promote physical activity.

62

63

64 Section 1: Introduction

65

66

67

68 1.1 BACKGROUND

69

70 The level of an individual's physical activity has a clear and strong association with physical
71 and mental health status. Those with sedentary lifestyles or with low levels of physical activity
72 are at a higher risk of a large number of conditions including coronary heart disease, stroke,
73 cancer and depression [1]. There are also additional benefits to increasing physical activity
74 such as walking and cycling through reducing the use of vehicles that present mortality risks
75 and pollute the environment.

76

77 The World Health Organization's (WHO) 2010 report on physical activity identified it as the
78 fourth leading risk factor in global mortality and liable for 6% of annual global mortality[2].
79 These figures do not include the quality of life reductions resulting from living with and being
80 treated for the health conditions that physical inactivity has caused, making this health burden
81 even greater. These health consequences translate into significant financial costs for the
82 National Health Service (NHS) and society in England; direct costs to the NHS are estimated
83 at £1.06bn and wider social costs at £6.5bn, stemming from lost productivity and premature
84 death resulting from sickness [3] [4].

85

86 The benefits of increasing physical activity in the population are reflected in its prominence in
87 public health campaigns. Since the National Institute for Health and Care Excellence (NICE)
88 began developing public health guidance in 2005, five guidelines have been produced,
89 covering numerous approaches to promoting physical activity including work place initiatives
90 (PH13) and interventions targeting children and young adults (PH17), and have identified a
91 number of cost-effective policies.

92

93 The work presented in this report contributes towards updating the guidance produced in 2008
94 on how the built and natural environment can be developed to improve physical activity levels
95 in the population (PH8). A *de novo* model is produced using updated evidence linking physical
96 activity to health outcomes and is able to evaluate the impact of interventions on low mobility
97 populations in addition to the general population. The aim of the model will be to present a
98 range of threshold analyses that will provide decision-makers with information on how cost-
99 effective an intervention will be for given levels of cost and physical activity improvement. The
100 cost-effectiveness of a number of case study interventions will also be evaluated to support
101 the Public Health Advisory Committee's updated recommendations.

102

103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125

1.2 OBJECTIVES

The economic model outlined in this report will contribute toward the achievement of the objectives set out in the NICE scope. The key questions from the scope are as follows:

- 1.** Which interventions in the built or natural environment are effective and cost-effective at increasing physical activity in the general population?
 - 1.1** Which transport interventions are effective and cost-effective?
 - 1.2** Which interventions related to the design and accessibility of public open spaces in the built and natural environment are effective and cost-effective?
- 2.** Does the effectiveness and cost-effectiveness of these interventions vary for different population groups (particularly those less able to be physically active)?
- 3.** Are there any adverse or unintended effects?
 - 3.1** How do these vary for different population groups (particularly those less able to be physically active)?
 - 3.2** How can they be minimised?
- 4.** Who needs to be involved to ensure interventions are effective and cost-effective for everyone?
- 5.** What factors ensure that interventions are acceptable to all groups?

Section 2: Methods

2.1 MODEL OVERVIEW

A cohort model was developed in line with the NICE methods manual and adopts a NHS and personal social services (PSS) perspective [5]. The model allows for various time horizons to be reported, and incorporates a lifetime time horizon in order to capture all relevant costs and benefits. Discount rates of 3.5% for both costs and benefits are applied to future costs and outcomes as stipulated in the NICE methods manual. The principal measure of cost-effectiveness is the incremental cost-effectiveness ratio (ICER), expressed as the incremental cost per quality-adjusted life year (QALY) of an intervention when compared with no intervention. This is defined as the ratio of the difference in cost and the difference in QALYs between the treatment, tx , and comparator, cx :

$$ICER = \frac{Cost_{tx} - Cost_{cx}}{QALY_{tx} - QALY_{cx}}$$

If the ICER is below the cost-effectiveness threshold, for which NICE uses a range of £20,000 to £30,000, then an intervention is deemed cost-effective. The cost-effectiveness threshold reflects the opportunity cost of lost health from areas as funds are moved to the new intervention that arises in fixed-budget health care systems. We also summarise results using net health benefit:

$$NHB = (QALY_{tx} - QALY_{cx}) - \frac{(Cost_{tx} - Cost_{cx})}{k}$$

Where k is an estimate of the cost-effectiveness threshold. NHB provides the net QALY per person QALY gain for a given level of the threshold: if NHB is greater than zero, the intervention will be cost-effective. We also provide disaggregated results that show both incremental costs and health-related quality of life (HRQOL) benefits.

The objective of the model is to identify the combinations of intervention cost and physical activity gain for which interventions will be cost-effective. These are summarised by determining a series of thresholds: the maximum intervention cost for it to be cost-effective for a given range of physical activity increases; and the minimum physical activity increase necessary for cost-effectiveness given the intervention cost. In addition, a number of case studies identified by the NICE evidence review and agreed with the Committee are modelled to assist with the recommendations.

The first stage of the model is based on previous work that has been carried out in the development of previous NICE guidance on physical activity (PH41). This approach estimates the continuous relationship between physical activity and mortality risk; increases in physical activity generated by an intervention can, therefore, be translated into increases in length of

169 life. To account for health gains experienced whilst alive, we extend the analysis to model
 170 impacts on the risk of developing five major diseases associated with low physical activity.
 171 Combined with long-term epidemiological data, we capture the lifetime complications
 172 associated these diseases.

173
 174

175 2.2 MODEL STRUCTURE

176


177 The model structure is shown in Figure 2.1. The population distribution of physical activity is
 178 estimated from Health Survey for England data from 2014, from which mean physical activity
 179 levels are calculated by age and gender. Metabolic equivalent time (MET) is used as the
 180 physical activity outcome measure, which adjusts the time spent on an activity according to its
 181 intensity. Successful interventions generate physical activity gains, for which a mean
 182 population gain is applied to the population, resulting in a post-intervention distribution of
 183 physical activity. Physical activity distributions are calculated for the general population and
 184 those with limited mobility using data from the 2014 Health Survey for England

185

186

187 **Figure 2.1: Model structure**

188



189

190 **Note:** CHD = coronary heart disease; QALY = quality-adjusted life year.

191

192

193 The pre- and post-intervention MET minutes for each subgroup are then plugged in to risk
 194 functions (see Sections 2.3.5 and 2.3.6) relating MET minutes per week with (i) mortality and
 195 (ii) five comorbidities linked to physical activity levels. From this we obtain the relative risk of
 196 death and disease from introducing the intervention for each age and gender subgroup. Since

197 these functions are continuous, the model allows for the impacts of even small changes in
198 physical activity to be estimated. The five comorbidities included in the model, which were
199 identified from the literature as being most commonly linked with physical activity levels [2],
200 are:

201

- 202 • Breast cancer;
- 203 • Colon cancer;
- 204 • Diabetes;
- 205 • Stroke;
- 206 • Coronary heart disease (CHD).

207

208 Two cohorts (one for the intervention and another for the comparator) then progress through
209 a simple Markov state-transition model, in which there are two states: alive or dead. In each
210 annual cycle individuals have a probability of death and probabilities of developing each of the
211 comorbidities, which are determined by the physical activity levels and risk functions described
212 above. Costs are determined by two factors: the initial intervention cost and the numbers
213 experiencing comorbidities, for whom a yearly cost is applied. The lifetime health of the cohort
214 is calculated by subtracting the expected QALYs lost due to experiencing disease from the
215 expected QALYs experienced by all those alive.

216

217 Cohorts progressing through the model are all the same age by design. However, given that
218 the kinds of interventions being considered are for the entire population, we run the model for
219 every year of age from 16 to 100. The costs and QALYs for each age are then weighted by
220 their relative population density and used to create weighted average estimates. These are
221 then used to estimate cost-effectiveness of each intervention relative to the comparator.

222

223 The computational burden of this approach means that probabilistic sensitivity, which captures
224 the combined uncertainty of all parameters simultaneously through Monte-Carlo simulation,
225 was not deemed practical. Instead, a wide range of deterministic sensitivity analyses are
226 conducted to establish the robustness of the results.

227

228

229 **2.3 MODEL INPUTS**

230

231 This section outlines the model inputs that have been used to populate the economic model
232 and also highlights any areas in which there are data gaps.

233

234 **2.3.1 Physical activity levels**

235

236 The Health Survey for England (HSE) 2014 was used to create physical activity distributions
237 for both the general population and those with limited mobility. The HSE is an annual series
238 of surveys that randomly samples a cross-section of the population and contains information
239 on a range of health, lifestyle and demographic factors.


240

241 In the 2014 survey this included the number of minutes per week spent by respondents on
242 moderate and vigorous physical activity. Of the 10,080 survey participants, we extracted

243 complete physical activity data for 6,452 individuals, as well as their age and gender. Of the
 244 3,628 exclusions, 3,425 were due to missing physical activity information and 138 due to
 245 missing health-related quality of life data, the use of which is outlined in Section 2.3.4. An
 246 additional 65 were excluded because their total moderate and vigorous activity minutes
 247 exceeded 12 hours per day, indicating that the question was likely misunderstood and the
 248 answer incorrect. A second sample of 1,113 individuals was extracted to form our limited
 249 mobility population, where limited mobility was defined as having either 'Some problems in
 250 walking about' or 'Confined to bed' on the mobility component of the EQ-5D questionnaire.

251
 252
 253
 254

Figure 2.2: Distribution of metabolic equivalent time (MET) minutes per week



255
 256 **Note:** Includes only moderate and vigorous activities

257
 258
 259
 260

Table 2.1: Light physical activity levels

Activity	N	Minutes		MET Minutes	
		Mean	Std. Dev.	Mean	Std. Dev.
Walking	1731	93	106	232	265
Gardening/Housework	1070	9	33	23	82
Total				255	278

261 **Note:** MET = metabolic equivalent time

262
 263
 264
 265
 266
 267

Following this we converted the moderate and vigorous activity minutes into MET minutes. For this we used the Compendium of Physical Activity (CPA), a resource detailing the conversion rate of one minute spent performing one of 821 activities into MET minutes [6]. Using WHO thresholds of 3-6 METs per minute for moderate activities and greater than six for

268 vigorous activities, we calculated the average METs per minute of all relevant activities in the
 269 CPA as 4.1 and 8.7, respectively [7]. The subsequent population distribution of MET minutes
 270 per week for both the general and limited mobility population is shown in Figure 2.2.

271
 272 Given that no data were available in the 2014 HSE on light activity, we used data on the time
 273 spent walking and performing housework and gardening from the 2012 survey as a proxy. The
 274 mid-point of the light activity range (2.5 METs per minute) was used to convert these minutes
 275 into MET minutes. We then assumed that light activity was a random variable with a gamma
 276 distribution and randomly drew values from it to assign individuals with additional METs per
 277 week. These light activity levels are reported in Table 2.1. The total mean MET minutes per
 278 week by age and gender are reported for our populations in Table 2.2 and

279
 280
 281 **Table 2.3.**

282
 283
 284 **Table 2.2: Mean metabolic equivalent time (MET) minutes per week**

285

Age	General population		Limited mobility population	
	Males	Females	Males	Females
16 to 24	5396	2854	3313	2861
25 to 34	5159	2562	4366	2446
35 to 44	4827	2639	3445	1016
45 to 54	4709	2945	2860	1665
55 to 64	4146	2919	2319	1670
65 to 74	3352	2013	1483	1018
75+	1907	1054	1250	564

286
 287
 288 The physical activity outcome measure that is incorporated into the model is the mean
 289 increase in MET minutes per week. In the base case, this gain will be applied uniformly to the
 290 whole population, as agreed during discussions with the Committee. However, it is understood
 291 that this is a contentious assumption, and so we assigned every individual a weight based on
 292 their physical activity ranking, an approach previously used by Minton et al [8]. These weights
 293 were characterised by a Beta distribution of the form $Beta(1 + \tau, 1 - \tau)$, in which τ indicates
 294 how the gains are distributed: when $\tau = 0$ all individuals gain equally, for $\tau > 0$ the most active
 295 gain more and for $\tau < 0$ the least active gain more. This relationship between the weights and
 296 τ is demonstrated in Figure 2.3. This shows, for a hypothetical intervention increasing mean
 297 activity by 50 MET minutes per week, the difference in increase across the activity distribution
 298 when τ takes on the values -0.1, 0 and 0.1. Different values of τ are used in both scenario and
 299 sensitivity analyses to show how the distribution of MET gain impacts upon cost-effectiveness.


300
 301 Our base case analysis assumes that the whole population maintains their increase in physical
 302 activity over their lifetimes. As this is another disputable assumption, we include in the model
 303 the option for the MET gain of a specified proportion of the population to decay. The decaying
 304 individuals are randomly selected and the decay rate can also be changed, so that anywhere
 305 between 0% and 100% of the gain is lost. When decay is factored into the model, it is applied

306 in the first cycle; for example, when decay is 100%, affected individuals lose all activity
307 improvements and receive no incremental health benefits from the intervention.

308
309

310 **Figure 2.3: Physical activity gain weighting function (for a mean increase of 50 MET**
311 **minutes per week)**

312



313
314 **Note:** MET = metabolic equivalent time

315
316

317 2.3.2 Effectiveness

318

319 Whilst the principal purpose of the model is to estimate which combinations of intervention
320 cost and MET increase are cost-effective, a number of case studies were identified from the
321 evidence review to be run through the model. Ideally, we would like the per person increase
322 in physical activity to be estimated for the local authority population that decision-makers will
323 operate in. However, only one of the seven studies modelled in this report recorded at the
324 town or city level; the remaining studies all survey populations local to the intervention location,
325 or, in one instance, survey route users only. The case studies were selected to represent five
326 broad intervention types highlighted by the PHAC:

- 327 1. Increase active travel / total physical activity through changes to transport
328 infrastructure (e.g. cycle lanes, traffic calming, busway);
- 329 2. Increase active travel / total physical activity through public transport frequency and
330 access (e.g. frequency and number of buses, number of stops, improved routes
331 including routes to green or blue space);
- 332 3. Increased active travel / incidental / total physical activity through reduction in vehicles
333 and vehicle speed (e.g. congestion charge, cyclovia, speed reduction);

- 334 4. Increase incidental / total physical activity through changes to open space access and
335 street design (e.g. including paths, trails, access/ signage, safe routes to schools);
336 5. Increased incidental / physical activity within existing green or blue space (woodlands,
337 parks, canal paths, coastal path, including access and facilities).
338

339 The studies evaluating interventions that reduced vehicle numbers or speed provided a
340 quantitative measure of physical activity that could not be converted into mean MET minutes
341 per week. This intervention type was not, therefore, represented in our case studies.
342 Summaries of the included studies are provided below, alongside a description of how the
343 mean MET increase was calculated from the outcomes reported in each study. The mean per
344 person increases in MET minutes per week for each study are reported in
345
346

347 **Table 2.3**

348
349 Four of the case studies were quality assessed by the evidence review team at NICE. Each
350 was given a minus score, indicating that the study did not satisfy a sufficient number of quality
351 criteria. In some instances, this was due to the observational, non-randomised nature of the
352 studies that is unavoidable when evaluating environmental interventions. However, other
353 sources of bias were identified, such as the risk of self-selection in the ‘Smarter Choices,
354 Smarter Places’ programme that arose due to towns applying for grants. The poorest quality
355 study we include is the park renovation evaluation conducted by Cohen et al., the methodology
356 of which was not adequately explained. The full quality assessment reports are provided in
357 the Effectiveness and Cost-Effectiveness Review documents: cycling demonstration towns,
358 fitter for walking and the greenway renovation studies are in Review 2 (‘Ciclovia’ and Street
359 Closures, Trails and Safe Routes to Schools), whilst Smarter Choices, Smarter Places and
360 the park renovation study are included in Review 3 (Park, Neighbourhood and Multicomponent
361 Interventions).
362

363 **Included Studies**

364 ***Sloman et al. (2009) – Cycling Demonstration Towns [9]***

365 For this intervention, funding was provided for cycling promotion and cycling infrastructure
366 improvements in six locations in the UK (Aylesbury, Brighton and Hove, Darlington, Derby,
367 Exeter and Lancaster). The interventions varied considerably, from the construction of a
368 pedestrian bridge to improved lighting and break areas for cyclists on existing trails, and falls
369 under the ‘changes to transport infrastructure’ theme. Data were collected on a range of
370 physical activity variables, with temporal trends controlled for by comparing each area with a
371 ‘matched’ town not included in the scheme. Quota sampling was used to select approximately
372 1,500 individuals living in each town.
373
374

375 The study reports that there was a 2.6% decrease in the proportion of the population reporting
376 physical activity levels that placed them in an ‘inactive’ group. As no formal definition was
377 provided for ‘inactive’, we assumed it referred to WHO guidelines on minimum recommended
378 levels of 150 minutes of moderate activity per week. To obtain the mean MET increase, two
379 assumptions were made: (i) only 2.6% of the population increased activity and (ii) their post-

380 intervention activity levels were equal to individuals whose activity levels were between 150
381 and 300 minutes of moderate activity per week. It is felt that the respective pessimistic and
382 optimistic nature of these assumptions will offset each other to some degree, limiting potential
383 bias.

384

385 We then multiplied 150 and 300 by 4.5, the mid-point of the MET minutes range for moderate
386 activity, to obtain the thresholds in MET minutes per week of 675 and 1350, respectively. The
387 2014 HSE is used to estimate the mean MET minutes for people with less than 675 (93) and
388 between 675 and 1350 (1001), with the difference representing the improvement in MET
389 minutes per week from moving from the inactive to active groups. Multiplying this by the
390 proportion transitioning gives the population mean MET increase:

391

$$(1001 - 93) \times 0.026 = 23.6$$

392

393

394

395 ***Norwood et al. (2009) – Smarter Choices, Smarter Places [10]***

396 This study evaluated a programme encompassing a series of interventions that aimed to
397 increase uptake of walking, cycling and public transport in seven local areas in Scotland.
398 Interventions included the introduction of new bus services, shelters and ticketing
399 improvements, with the study representing the ‘public transport frequency and access’ theme.
400 Temporal trends are once again controlled for by comparing each area with a ‘matched’ town
401 outside of the scheme. Between 8% and 10% of each local area were randomly selected to
402 be included in the pre- and post-intervention surveys. Physical activity is measured by the
403 proportion meeting physical activity guideline levels – here explicitly given as 150 minutes of
404 moderate exercise per week.

405

406 Compared with the control areas, the proportion meeting guidelines increased by 11.5%. As
407 the activity thresholds are identical to the Cycling Demonstration Towns study, the same
408 calculations and numbers can be used to obtain the mean MET increase for the general
409 population, updating only the proportion transitioning to the active group:

410

$$(1001 - 93) \times 0.115 = 104.4$$

411

412

413

414 ***Adams and Cavill (2015) – Fitter for Walking [11]***

415 The Fitter for Walking scheme involved infrastructural changes, community activities and
416 promotional activities to increase walking in 12 locations in the UK. The study, which
417 represents the ‘open access and street design’ theme, evaluated five of these sites and
418 reported the relative increases in the number of pedestrians using affected trails and
419 walkways. No control group is used to account for temporal changes, meaning that the results
420 are more vulnerable to bias. Another source of bias is that activity gains are calculated by
421 surveying route users rather than a random sample of a defined population. This is likely to
422 overestimate the activity gains as it does not account for the local population not using the
423 facilities.

424

425 The authors report a 14.9% increase in pedestrian activity on the monitored routes. To
426 calculate the mean MET increase, we used data on the mean number of weekly walking trips
427 and mean walking trip length from the National Transport Survey, as reported in Brennan *et*
428 *al.* This is used to estimate the average weekly time spent walking for an additional pedestrian.
429 This is multiplied by 3.5, the MET minutes for one minute of brisk walking and 14.9%, the
430 additional number of pedestrians to obtain the mean population increase in MET:

431

432

$$3.5 \times 44.7 \times 0.149 = 23.3$$

433

434 ***Cohen et al. (2015) – Park renovation [12]***

435 This study investigated the impact of park renovations on moderate and vigorous activity in
436 San Francisco in the USA and is included here as part of the ‘green or blue space’ theme. Six
437 parks were included in this controlled before-and-after study: two that were renovated, two
438 partially renovated and two not renovated. Improvements to the park included new outdoor
439 fitness equipment and play areas and renovated recreational grounds.

440

441 The researchers monitored activity throughout the day for seven days a week and directly
442 recorded the number of minutes of moderate and vigorous activity performed by park users.
443 As with the Fitter for Walking intervention, this is likely to overestimate the activity gains as it
444 does not account for local residents not using the park. The authors also note that one of the
445 control parks decreased in observed activity at follow up due to more restrictive opening hours
446 – we therefore assumed that the control parks saw no change to remove this factor. Activity
447 time was converted into and reported as MET hours per person at baseline, with the effect of
448 renovation reported as a percentage increase. This yielded a mean increase of 4.5 MET
449 minutes per person.

450

451 ***Dallat et al. (2013) – Connswater Community Greenway [13]***

452 The Connswater Community Greenway was a four year regeneration project that took place
453 in Belfast, Northern Ireland, with the explicit objective of increasing physical activity. The
454 intervention included the construction of nearly 20 kilometres of cycle paths and walkways and
455 improved access to green space.

456

457 The study used a quasi-experimental survey to estimate physical activity changes, randomly
458 sampling 1,209 households defined as being ‘in the vicinity’ of the greenway, compared to
459 control group of individuals from the rest of Northern Ireland. It was found that the intervention
460 increased the proportion of those achieving 150 minutes or more of exercise a week by 5%.
461 We therefore convert the increase into MET minutes per week using the same method as that
462 used for Cycling Demonstration Towns, resulting in the following calculation:

463

464

$$(1001 - 93) \times 0.05 = 45.4$$

465

466 ***West & Shores (2011) – New greenway [14]***

467 This study evaluated the physical activity impacts of constructing five miles of greenway along
468 a river in an unnamed city in United States. No further details are provided on the renovations
469 by the authors.

470

471 A total of 1,168 households located within one mile of the greenway were randomly selected
472 for pre- and post-intervention surveys, of which 168 (14.2%) responded to both. The authors
473 then report matrix showing, both before and after the intervention, how many participants
474 partook in walking or moderate and vigorous exercise, and the respective frequency in the
475 preceding week. From this we calculated the change in the mean number of days per
476 participant that each activity was undertaken. Using data on average daily MET minutes of 33,
477 158 and 276 for walking, moderate exercise and vigorous exercise, respectively, the change
478 in MET minutes per week could be estimated by the following calculation:

479

$$(0.38 \times 33.2) + (0.56 \times 158) + (0.46 \times 276) = 229$$

481

482 ***Chomitz et al. (2012) – Active Living By Design [15]***

483 The Active Living By Design programme was a multicomponent intervention implemented in
484 cities in the United States in 2007. However, we use only the results from the one city,
485 Somerville, which had a before and after component. The intervention included new signage,
486 park renovations and the creation of new walking paths alongside a well-funded promotional
487 campaign.

488

489 Two random samples of the Somerville population were surveyed in 2002 and 2008, totalling
490 1,725 adults. The physical activity measure reported by the authors is the proportion meeting
491 moderate and/or/ vigorous physical activity guidelines, defined as 150 and 60 minutes,
492 respectively. They found that there was a 22% increase in the number meeting these
493 guidelines. Using the technique described for previously, we use this proportion to calculate
494 the mean MET minutes per week increase:

495

$$(1001 - 93) \times 0.22 = 200$$

497

498 ***Woods In and Around Towns (WIAT)***

499

500 This study evaluated the effects on physical activity of the Woods In and Around Towns
501 programme funded by the Forestry Commission Scotland. The objective of the WIAT
502 programme is to increase the use of woodland by local populations. The intervention involves
503 two stages: (i) making physical changes to woodlands to increase the aesthetic and practical
504 appeal of the space and (ii) conducting activities in the community to promote woodland use
505 and engage the local population.

506

507 Six sites were selected for the study, divided evenly between intervention and control arms.
508 The sites were selected so that a substantial proportion of the local population were in the
509 most deprived 30% of the general population. Households within a 1.5 kilometre radius of
510 each site were then randomly sampled and asked to complete the short-form International
511 Physical Activity Questionnaire, the responses of which were converted into MET minutes per
512 week by the researchers. Regression analyses were then performed on the individual-level
513 data to ascertain the impact of the intervention on physical activity. The researchers found
514 that, after the physical and social components of the intervention had been implemented, MET
515 minutes per week were **XXX** higher in the intervention arm. This increase was viewed by the
516 Committee as implausibly large, so a secondary analysis was conducted that used only the

517 change in activity due to walking. A similar analysis from the authors indicate that this increase
518 is **XXX** MET minutes per week.

519
520
521
522
523
524
525
526

Table 2.3: Increases in mean metabolic equivalent time (MET) minutes per week for selected case studies

Intervention	Study	Mean MET increase
Cycling Demonstration Towns	Sloman <i>et al.</i> (2009) [9]	23.6
Smarter Choices, Smarter Places	Norwood <i>et al.</i> (2014) [10]	104.4
Fitter for Walking	Adams & Cavill (2015) [11]	23.3
Park renovation	Cohen <i>et al.</i> (2015) [12]	4.5
Connswater Community Greenway	Dallat <i>et al.</i> (2013) [13]	45
New greenway	West & Shores (2011) [14]	229
Active Living By Design	Chomitz <i>et al.</i> (2011) [15]	200
Woods In and Around Towns	Thompson and Brookfield (forthcoming)	XXX
Woods In and Around Towns (walking activity only)	Thompson and Brookfield (forthcoming)	XXX

527
528
529
530

2.3.3 Costs

Comorbidity costs

532 Comorbidities are incorporated into the model using the prevalent rather than the incident
533 population. This is because we need to estimate the proportion of the cohort with each
534 comorbidity in each cycle, rather than only new cases. However, the prevalent population can
535 cover a wide variety of patient types and resource use, such as cancer patients with metastatic
536 disease compared with those in remission. We therefore sought estimates of annual national-
537 level expenditure for each comorbidity and divided this by the estimates of the prevalent
538 population to generate the yearly costs for a hypothetical average patient.

539
540 The annual costs associated with each comorbidity and the data sources used to calculate
541 them are provided in Table 2.4. The costs reflect the on-going annual costs and are multiplied
542 by the number of people with each comorbidity each cycle.

543
544 The comorbidity cost sources were reviewed to identify if social care costs were included, and
545 if so whether these costs could be disaggregated. However, given that not all cost sources
546 reported the disaggregated costs it was not possible to report overall costs for social care
547 separately and, therefore, results are reported for NHS and personal social services as a
548 whole.

549
550
551

Table 2.4: On-going annual comorbidity costs per person (NHS)

Parameter	Cost	Source
Breast cancer	£2,363	National expenditure: Breast cancer expenditure by Programme Budgeting Category and Primary Care Trust. Department of Health [16] Inflated from 2013/14 to 2015/16 prices using PSSRU (2016) H&CHS indices [17] Patient population: Maddams <i>et al.</i> (2008) [18]
Colon cancer	£1,153	National expenditure: Trueman <i>et al.</i> (2007) [19] Inflated from 2006/07 to 2015/16 prices using PSSRU (2016) H&CHS indices [17] Patient population: Maddams <i>et al.</i> (2008) [18]
Diabetes	£2,338	National expenditure: Hex <i>et al.</i> (2012). [20] Inflated from 2010/11 to 2015/16 prices using PSSRU (2016) H&CHS indices [17] Patient population: Public Health England [21]
Stroke	£5,653	NICE CG92 Full guideline [22]. Inflated from 2007/08 to 2015/16 prices using PSSRU (2016) H&CHS indices [17]
CHD	£1,394	National expenditure: British Heart Foundation. Cardiovascular Disease Statistics [23] Inflated from 2012/13 to 2015/16 prices using PSSRU (2016) H&CHS indices [17] Patient population: British Heart Foundation [23]

553 **Note:** PSSRU = Personal Social Services Research Unit

554

555

556 **Intervention costs**

557 Per person intervention costs for the selected case studies are provided in Table 2.5. These
558 were extracted from the effectiveness studies and supporting documents where available.
559 Maintenance costs were not specified in any of the studies and are not therefore included; the
560 impact of these are therefore explored in a scenario analysis. For studies where only total
561 intervention cost was provided, a per person intervention cost was only calculated when a
562 population size was explicitly provided. Therefore, no intervention cost could be calculated for
563 the 'Fitter for Walking' scheme. For the greenway intervention evaluated by West & Shores,
564 no costs are provided at all. In all but one study where costs could be calculated, the population
565 matched the one used to calculate effectiveness. However, in the park renovation evaluated
566 by Cohen *et al.*, it is likely that park user surveys included those living outside of half a mile
567 from the park, the population used to calculate the average cost. Lastly, as the park renovation
568 study and Active Living by Design were conducted in the USA, the intervention costs were
569 converted from dollars into pound sterling at an exchange rate of 0.77. This, along with the
570 questionable transferability of US infrastructure cost to a UK setting, mean that these
571 intervention costs should be treated with additional caution.

572

573

574 **Table 2.5: Intervention costs for selected case studies**

575

Intervention	Study	Cost per person
Cycling Demonstration Towns	Sloman <i>et al.</i> (2009) [9]	£11.64
Smarter Choices, Smarter Places	Norwood <i>et al.</i> (2014) [10]	£96.59
Fitter for Walking	Adams and Cavill (2015) [11]	N/A
Park renovation	Cohen <i>et al.</i> (2015) [12]	£203.44

Intervention	Study	Cost per person
Connswater Community Greenway	Dallat et al. (2013) [13]	£71.87
New greenway	West & Shores (2011) [14]	N/A
Active Living By Design	Chomitz et al. (2011) [15]	£42.99
Woods In and Around Towns	Thompson and Brookfield (forthcoming)	£XXX

576

577

578 Furthermore, it was felt by the PHAC that intervention costs will have substantial variability
579 across settings even within the UK. Therefore, for each intervention we conduct a threshold
580 analysis to determine the maximum price at which it will be cost-effective. These are presented
581 alongside the central estimate.

582

583

584 2.3.4 Utilities

585

586 We modelled health-related quality of life as a function of physical activity time as well as age
587 and gender, as is normally done in cost-effectiveness analyses. This was done to capture the
588 effects of physical activity on comorbidities not included in the model and on general health
589 aspects not related to a particular condition, such as mental well-being.

590

591 Our HRQOL measure, as recommended in the NICE methods manual, is the EuroQol five
592 dimension (EQ-5D) questionnaire and is included in the same HSE data from which we
593 estimated the physical activity distribution. We are thus able to estimate the statistical
594 relationship between EQ-5D score and age, gender and MET minutes per week using the
595 following OLS regression model:

596

597

$$HRQOL_i = \beta_1 + \beta_2 age_i + \beta_3 gender_i + \beta_4 MET_i + \varepsilon_i$$

598

599 In which the β 's are the estimated regression coefficients that quantify the impact of the
600 variable on HRQOL and ε_i is the random error for each individual i . Prior to estimating the
601 equations for each population (general and limited mobility), we first removed the individuals
602 who have reported heart and circulatory conditions and diabetes. This is to strip out the impact
603 of MET on HRQOL that would be associated with the five comorbidities included in the model,
604 which are accounted for separately. The regression output is reported in Table 2.6. The EQ-
605 5D scores were then calculated for age and gender groups by plugging their respective mean
606 MET minutes per week from Table 2.2 into the equations. These predicted utility values are
607 given in Table 2.7. For both populations, an additional MET minute per week increases utility,
608 whilst being male is also associated with a higher score. In the general population, utility
609 decreases monotonically from age 34 and above. Interestingly, older age groups in the limited
610 mobility population have a higher predicted HRQOL. Whilst this could be due to random
611 chance stemming from the small sample size or selection bias, it may also be due to the fact
612 that limited mobility in older age is more commonly a result of attrition (for instance, joint
613 deterioration), whereas for younger age groups, it is more likely to be the result of a debilitating
614 chronic condition. Furthermore, elder populations may have also adapted better to limiting
615 conditions and report higher HRQOL. It is therefore plausible that HRQOL could be lower for
616 younger groups in this population.

617 In order to estimate the effect of developing a comorbidity on HRQOL, we undertook searches
618 to identify estimates of the utility values associated with each of the five conditions contained
619 in the model. These utility values, and their source are reported in Table 2.8. From these we
620 calculate the disutility (the utility loss associated with living with the condition for one year).
621 These are calculated by subtracting the disease-specific utility from that of someone in good
622 health. For the latter, we use the utility value of the age group that matches the mean age of
623 the sample from which the disease-specific utility is estimated to calculate the disutility. For
624 example, the breast cancer utility of 0.77 provided in Hall *et al.* is calculated from a sample
625 with a mean of 66. The disutility for females is then the difference between this and the healthy
626 utility score for 65 to 74 year olds of 0.83, or 0.06. This disutility is then applied to anyone
627 experiencing the condition, regardless of age, gender or whether they have limited mobility.
628 Furthermore, we assume that the effect on HRQOL of experiencing multiple comorbidities,
629 which some people invariably will, is additive. In other words, women who develop breast
630 cancer and diabetes will have a yearly disutility of $0.063+0.165=0.228$.

631
632
633
634

Table 2.6: Effect of age, gender and MET minutes per week

	EQ-5D Score (general population)	EQ-5D Score (limited mobility population)
N	5,429	715
Variable		
Constant	0.906*** (0.007)	0.528*** (0.049)
Male	0.024*** (0.005)	0.023 (0.021)
MET minutes per week	0.03×10^{-4} *** (0.01×10^{-4})	0.08×10^{-4} ** (0.03×10^{-4})
<i>Age</i>		
25 to 34	0.002 (0.008)	-0.028 (0.059)
35 to 44	-0.024** (0.009)	-0.016 (0.057)
45 to 54	-0.042*** (0.009)	0.002 (0.055)
55 to 64	-0.078*** (0.011)	-0.127* (0.056)
65 to 74	-0.080*** (0.011)	0.017 (0.052)
75+	-0.151*** (0.015)	0.022 (0.052)

635
636
637
638
639
640

Notes:

1. Standard errors in parentheses.
2. *** P<0.001 ** P<0.01 * P<0.05
3. MET = metabolic equivalent time

641 Along with the QALY losses associated with living with diseases, we also wanted to capture
642 the losses that result from premature death. This was done using estimates of life expectancy
643 from Office for National Statistics (ONS) life tables [28] and the EQ-5D population norms
644 calculated by Kind *et al* [29]. Firstly, life expectancy by single year of age was extracted to
645 obtain the number of life years lost of a person dying at that age. Each year of life was then
646 weighted by the EQ-5D score from the population norms by age and gender to adjust for
647 quality of life. These were then discounted at a rate of 3.5% per year in accordance with the
648 NICE methods manual. The resulting values, representing the total discounted QALYs lost
649 from dying at any age, are subsequently applied to any deaths occurring in the cohort. The
650 discounted and undiscounted QALY loss by age at death are shown in Figure 2.4.

651
652
653
654
655
656
657
658

Table 2.7: Predicted EQ-5D utility scores for healthy individuals

Age	General population		Limited mobility population	
	Males	Females	Males	Females
16 to 24	0.94	0.91	0.58	0.55
25 to 34	0.94	0.91	0.53	0.50
35 to 44	0.92	0.89	0.55	0.52
45 to 54	0.90	0.87	0.57	0.54
55 to 64	0.86	0.84	0.44	0.41
65 to 74	0.86	0.83	0.58	0.55
75+	0.78	0.76	0.58	0.55


659
660
661
662

Table 2.8: Comorbidity utility and disutility values

Comorbidity	Utility	Disutility		Source
		Males	Females	
Breast cancer	0.772	0.087	0.063	Hall <i>et al.</i> (2015) [24]
Colon cancer	0.793	0.066	0.042	Hall <i>et al.</i> (2015) [24]
Diabetes	0.670	0.191	0.165	Janssen <i>et al.</i> (2011) [25]
Stroke	0.440	0.419	0.393	Golicki <i>et al.</i> (2015) [26]
CHD	0.760	0.099	0.073	Stevanovic <i>et al.</i> (2016) [27]

663
664
665
666

Figure 2.4: Quality-adjusted years of life lost by age at death



667
 668 **Note:** Discount rate of 3.5% was applied
 669

670
 671

672 2.3.5 Comorbidity Epidemiology

673

674 As the cohort progresses through the model and grows older, their risk of developing
 675 comorbidities will also change. These risks are also dependent upon an individual's level of
 676 physical activity. We therefore required information on the prevalence of each condition by
 677 age and gender and the dose-response relationship between risk and physical activity level,
 678 so that these changing risks could be incorporated into the model.

679

680

681 **Table 2.9: Sources for prevalence of comorbidities**

682

Comorbidity	Source for prevalence rates
Breast cancer	Maddams <i>et al.</i> (2009) [18]
Colon cancer	Maddams <i>et al.</i> (2009) [18]
Diabetes	Diabetes UK. 'Diabetes in the UK 2012: Key statistics on diabetes' [30]
Stroke	Bhatnagar <i>et al.</i> (2015) [31]
CHD	Liu <i>et al.</i> (2002) [32]

683 **Note:** Breast cancer prevalence was not reported for males. To calculate this, we multiplied the female
 684 rates by 0.007, as reported by Cancer Research UK [33].

685

686

687 Table 2.9 summarises the sources used to obtain the prevalence rates of each comorbidity.
 688 Where the age groups were aggregated at a higher level than the seven groups we use in the
 689 model, we assumed the rate was constant across contained age bands. For example, where
 690 cancer prevalence was given for 0 to 44 in Maddams *et al.*, we applied this rate to the 16 to

691 24, 25 to 34 and 35 to 44 groups [18]. The prevalence rates by age and gender for all
 692 comorbidities are provided in Table 2.10 and Table 2.11.

693

694

695 **Table 2.10: Prevalence of breast and colon cancer by age and gender**

Age	Breast cancer		Colon cancer	
	Males	Females	Males	Females
16 to 24	0.01%	0.14%	0.01%	0.01%
25 to 34	0.01%	0.14%	0.01%	0.01%
35 to 44	0.01%	0.14%	0.01%	0.01%
45 to 54	0.19%	2.69%	0.34%	0.26%
55 to 64	0.19%	2.69%	0.34%	0.26%
65 to 74	0.40%	5.69%	2.24%	1.65%
75+	0.40%	5.69%	2.24%	1.65%

696 **Note:** Male breast cancer rates were assumed to 0.7% that of women at all age groups

697

698

699 To determine how these risks change following an increase in physical activity, we sought
 700 evidence that linked the relative risk of developing comorbidities to physical activity level. In
 701 the end, one study by Kyu *et al.* provided all the required evidence [34]. In this study the
 702 authors performed a systematic review and meta-analysis for each comorbidity that
 703 incorporated a total of 174 articles: 35 for breast cancer, 19 for colon cancer, 55 for diabetes,
 704 43 for ischemic heart disease and 26 for stroke. Strong associations were found between
 705 physical activity and risk of each disease, with the largest reductions occurring when initial
 706 physical activity levels were low.

707

708

709 **Table 2.11: Prevalence of type-2 diabetes, stroke and CHD by age and gender**

Age	Diabetes		Stroke		CHD	
	Males	Females	Males	Females	Males	Females
16 to 24	1.80%	2.10%	0.11%	0.11%	0.10%	0.00%
25 to 34	1.80%	2.10%	0.11%	0.11%	0.40%	0.30%
35 to 44	9.40%	6.60%	0.11%	0.11%	0.90%	0.60%
45 to 54	9.40%	6.60%	0.89%	0.79%	4.30%	1.80%
55 to 64	11.1%	8.00%	2.69%	1.96%	13.6%	6.30%
65 to 74	15.2%	12.2%	6.40%	4.39%	20.2%	12.5%
75+	15.9%	13.2%	14.9%	12.4%	23.4%	18.4%

710 **Note:** CHD = coronary heart disease

711

712

713 The authors, however, provide these relative risk reductions at 50 discrete intervals of MET
 714 minutes per week from 0 to 30,000, with each value being relative to 0 METs per week. This
 715 meant that we were required to fit curves to the reported data in order to obtain the continuous
 716 relationship between them. For each comorbidity, we therefore estimated the linear-log
 717 relationship in a regression model of the form:

718

719

$$RR_{cj} = \alpha_1 + \alpha_2 \log(MET_j) + \varepsilon_j$$

720

721 Where RR_{cj} is the relative risk for comorbidity c at interval j , ε_j is the random error and α_2
 722 relates the relative risk to MET minutes per week. For each model, we set the reference MET
 723 value to 1 instead of 0 to avoid estimation errors when using $\log(0)$.

724
 725 We estimate two further sets of equations for each comorbidity, using the upper and lower
 726 confidence intervals of the relative risks at each interval reported by Kyu *et al.* These provide
 727 an upper and lower estimate of the impact of $\log(MET)$ on relative risk, which we then use in
 728 sensitivity analyses. The results of all of these regression models are provided in Table 2.12.

729
 730
 731 These equations then allowed us to create continuous functions, from which the relative risk
 732 reduction of any increase in physical activity can be calculated. These are shown in Figure
 733 2.5. It is assumed that the change in comorbidity risk is transferred instantaneously and that
 734 the same relative risk reductions occur for the limited mobility population. From here, the
 735 process of calculating the relative risk reduction of increase in MET from any starting level of
 736 MET is straightforward:

- 737
 738 (i) Calculate the relative risk of the baseline MET relative to the reference level (1
 739 MET minute);
 740 (ii) Calculate the relative risk of the post-intervention MET relative to the reference
 741 level;
 742 (iii) Divide (ii) by (i) to obtain the relative risk of the intervention MET compared with
 743 the baseline level.

744
 745

746 **Table 2.12: Effect of log(MET minutes per week) on the relative risk of developing**
 747 **comorbidities**

748

	Breast Cancer	Colon Cancer	Diabetes	Stroke	CHD
Constant	1.110	1.088	1.108	1.073	1.016
ln(MET)	-0.024	-0.031	-0.040	-0.037	-0.030
Lower 95% CI					
Constant	1.095	1.092	1.114	1.140	1.043
ln(MET)	-0.017	-0.024	-0.035	-0.033	-0.026
Upper 95% CI					
Constant	1.120	1.076	1.108	1.026	0.985
ln(MET)	-0.031	-0.036	-0.045	-0.043	-0.034


749 **Note:** MET = metabolic equivalent time

750

751

752 **Figure 2.5: Effect of MET minutes per week on relative comorbidity risk**

753



754

755

Note:

756

1. BC = breast cancer; CC = colon cancer; CHD = coronary heart disease.

757

2. Metabolic equivalent time (MET) minutes per week adjusts time spent being active by the relative intensity. For instance, 700 METs are equivalent to 200 minutes each week of leisurely walking.

758

759

3. Risks relative to a reference level of 1 MET minute per week

760

761

762

763

2.3.6 Mortality Epidemiology

764

765

This section describes how the reduced mortality risk associated with additional physical activity is handled in the analysis.

766

767

768

As with comorbidity risk, mortality risk will increase as individuals' age and progress through the model. We were therefore tasked with finding data on the current mortality risks in the population and to identify evidence linking these risks to physical activity levels. For baseline mortality risks, we used Office for National Statistics (ONS) data on mortality rate by gender and single year of age [28].

770

771

772

Since the mortality impact of comorbidities is not explicitly modelled, we analyse mortality from all causes. This was advantageous as we were not required to strip out disease-specific mortality from the baseline mortality rates and could utilise the study by Anderson *et al.* that links physical activity to all-cause mortality [35]. This has been used previously in both the WHO's health economic assessment tool for walking and cycling interventions, and the analysis in PH41 by Brennan *et al* [36].

773

774

775

776

777

778

779

780

781

Table 2.13: Conversion of activity thresholds from Anderson *et al.* (2000) into MET minutes per week

782

783

784

Activity threshold	Study definition	MET threshold	Assumptions
Low	Entirely sedantary / less than two hours light activity per week	150	Mid-point of light activity range (2.5) multiplied by mid-point of activity range (60 minutes)
Moderate	Light activity 2-4 hours per week	630	CPA estimate of 3.5 METs for leisure cycling and walking multiplied by mid-point of activity range (180 minutes)
High	Greater than 2 hours vigorous activity per week	Varied by age and gender	Average vigorous minutes per week for those doing more than 120

785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801

The Anderson *et al.* study followed a sample of 30,640 individuals for an average of 14.5 years and estimated the relative risk of death by physical activity level for six age and gender subgroups in a multivariate analysis to adjust for potential confounders. Individuals were grouped into one of three physical levels – low, moderate and high. These were based on loose threshold descriptions of weekly activity that required us to make several assumptions when converting them into MET minutes per week. The study thresholds, assumptions and our MET thresholds are provided in Table 2.13.

Table 2.14: Mortality by smoking status

	Males			Females		
	20 to 44	45 to 64	65+	20 to 44	45 to 64	65+
Constant	1.257	1.259	1.438	1.459	1.419	1.638
ln(MET)	-0.065	-0.064	-0.105	-0.099	-0.094	-0.147
Lower 95% CI						
Constant	1.040	1.150	1.304	1	1.290	1.476
ln(MET)	-0.010	-0.038	-0.073	0	-0.064	-0.112
Upper 95% CI						
Constant	1.461	1.342	1.551	1.766	1.542	1.775
ln(MET)	-0.113	-0.084	-0.131	-0.169	-0.121	-0.176

802
803
804
805
806
807
808
809
810
811


These provided three data points for each of the age and gender groups, from which we estimated regression equations in the same way as was done for comorbidity risk in the previous section. Anderson *et al.* also provide 95% confidence intervals for their relative risk estimates, which we use to re-estimate the risk equations to provide the lower and upper bounds on the impact of MET minutes on mortality risk for each group. The results from all these regressions are reported in Table 2.14, with the continuous functions estimated from the equations plotted in Figure 2.6. The same process for estimating the risk of death at the intervention-level MET relative to the comparator is used as for comorbidity risk. As with the

812 relative risks for the comorbidities, it is assumed that the change in risk happens in the first
813 cycle and that the same curves apply to the limited mobility population.

814
815

816 **Figure 2.6: Effect of MET minutes per week on relative mortality risk**

817



818
819

Note: Risks relative to a reference level of 150 MET minutes per week

820 Section 3: Results

821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864

The results in this section are representative of the average age and gender in the general population, unless stated otherwise and are reported for a lifetime time horizon from the perspective of the NHS. The principal results are a series of scenario and threshold analyses that determine what combinations of MET improvement and intervention cost represent cost-effective use of resources. Our scenarios also show how cost-effectiveness is affected by the distribution of MET increases in the population, the value of the cost-effectiveness threshold and the proportion of the population for whom MET increases decay. The results of our case study evaluations are also shown. Throughout the results, net health benefit is calculated using a threshold of £20,000 per QALY, except during the threshold scenario analysis.

3.1 SCENARIO ANALYSIS

3.1.1 Intervention cost and activity gain


The following scenario analysis varies the mean MET improvement associated with an intervention, the cost of the intervention. This allows a variety of scenarios to be assessed and to observe their effect on the results. The following scenario analyses, shown in full in Table 3.1, assume that the comparator is no intervention (i.e. baseline levels of MET minutes per week.) Our analysis also varied the distribution of activity gain between favouring the less active ($\tau=-0.1$), uniform ($\tau=0$) and favouring the more active ($\tau=0.1$). However, this had minimal effect and did not substantively alter the points at which interventions became cost effective.

Figure 3.1 shows that when the cost of an intervention increases, or when the effectiveness decreases, the NHB becomes lower. It is clear that, when the cost per person of the intervention is low, only modest gains in MET minutes per week are required in order for it be cost-effective. For an intervention cost of £10 per person for instance, an intervention need only increase activity by an average of 2 MET minutes per week – the equivalent of an additional one minute of light strolling per week. This increases to 23 and 59 MET minutes per week for interventions costing £100 and £250 per person, respectively.

The same analysis is conducted for low mobility populations and is shown in Figure 3.2. At low intervention costs, the required MET gain for cost-effectiveness is similar at around 1.5 MET minute per week. At higher intervention costs however, cost-effectiveness is achieved at far lower mean MET minute increases: when the cost is £100 the required MET increase falls from 23 for general population to 16; at intervention costs of £250 the respective fall is from 59 to 41.

865 **Figure 3.1: MET gain and cost scenario analysis (general population)**

866




867

868

869

870 **Figure 3.2: MET gain and cost scenario analysis (limited mobility population)**

871



872

873

874

875 **3.1.2 Activity gain decay, maintenance costs and the cost-effectiveness threshold**

876

877 Figure 3.3 shows how the relationship between NHB, interventions costs and MET increases
878 when the activity gains of 25% of the population immediately decay to half the initial increase.
879 The minimum MET increase required for cost-effectiveness increases at each intervention
880 cost: from 2 to 3 minutes for an intervention cost of £10 per person and from 59 to 67 for an
881 intervention cost of £250 per person.


882

883

884

Figure 3.3: MET gain and cost scenario analysis (50% MET gain decay)

885



886

887

888 Two scenarios were run to consider the impact of maintenance costs on net health benefit.
889 These are applied in each annual cycle and are calculated as proportion of the total
890 intervention cost. This is informed by evidence from Sustrans [37] and the National Audit Office
891 [38] that estimate annual maintenance costs somewhere between 1% and 5% of initial
892 infrastructure costs; we therefore use these as our scenario values. The results, presented in

893 Figure 3.4 and Figure 3.5, show that the minimum MET increase required for cost-
894 effectiveness increases marginally for small intervention costs and substantially for higher
895 intervention costs. At intervention costs of £25 per person, the required increase rises from 6
896 in the base case to 7 and 11 for maintenance costs of 1% and 5% respectively. At intervention
897 costs of £250 per person, the required increase rises from 59 in the base case to 69 and 112
898 for maintenance costs of 1% and 5% respectively.

899


900

901

902

903 **Figure 3.4: MET gain and cost scenario analysis (1% maintenance costs)**

904




905

906

907

908 **Figure 3.5: MET gain and cost scenario analysis (5% maintenance costs)**

909



910

911


912

913 The effect of changing the cost-effectiveness threshold from £20,000 to £30,000 and £10,000
914 per QALY are shown in Figure 3.6 and Figure 3.7, respectively. This change in threshold
915 implies that the losses, in terms of health, of displacing other services to fund the new
916 intervention are lower (£30,000) and higher (£10,000) than those of our base case. As
917 expected, lower health opportunity costs mean that interventions with lower activity increases
918 are also cost-effective; higher opportunity costs have the opposite effect. For example, as the
919 threshold moves from £30,000 to £10,000, the minimum mean MET increase required for cost-
920 effectiveness increases from 1.5 to 5 for interventions costing £10 per person, and from 15.5

921 to 48 for interventions costing £100 per person. The effects of changing opportunity costs are
 922 much greater at higher intervention costs are higher and is shown by the greater spread of the
 923 lines.


924
 925

926 **Figure 3.6: MET gain and cost scenario analysis (cost-effectiveness threshold at**
 927 **£30,000)**



929
 930
 931
 932
 933
 934
 935

933 **Figure 3.7: MET gain and cost scenario analysis (cost-effectiveness threshold at**
 934 **£10,000)**



936
 937
 938

939
940
941
942

Table 3.1: Summary of MET minutes per week required for an intervention to be cost-effective by scenario and intervention cost

Scenario	Intervention cost				
	£10	£25	£50	£100	£250
Base case	2.5	6	11.5	23	59
Limited mobility population	1.5	4	8	16	41
50% decay of activity gain	5	11	23	47	119
1% maintenance costs	3	7	13	27	69
5% maintenance costs	4	11	22	45	112
CET = £30,000	1.5	4	8	15.5	38.5
CET = £10,000	5	12	24	48	>100

943
944
945
946
947
948

Notes:

1. CET = cost-effectiveness threshold; MET = metabolic equivalent time
2. The base case refers to a scenario for the general population in which CET=£20,000, no treatment effect decay is implemented and there activity gains are uniform across the population ($\tau=0$)

949

3.2 CASE STUDY RESULTS

950

The cost-effectiveness summaries and cost threshold analyses are provided in Tables 3.2 to 3.6 and Figures 3.6 to 3.12, respectively. The Woods In and Around Towns programme is the most cost-effective intervention and yields an ICER of £XXX. The multicomponent interventions are the next best: Cycling Demonstration Towns, Smarter Choices, Smarter Places and Active Living by Design yield ICERs of £2,496, £4,423 and £1,397, respectively. The Connswater Community Greenway is also cost-effective at an ICER of £7,652. With a US-based intervention cost estimate of over £200 per person, park renovations are not cost-effective, with an ICER of £215,989.

951

952

The cost thresholds, meanwhile, indicate the maximum intervention cost that an intervention can be for it to be cost-effective. Cycling demonstration towns and the Fitter for Walking scheme are nearly identical in this respect, with cost thresholds of approximately £100. Owing to much greater health benefits (0.025 QALYs versus 0.003 and 0.004 QALYs), the Smarter Choices, Smarter Places scheme remains cost-effective at intervention costs of up to around £440 per person. The Connswater Community Greenway, meanwhile, is cost-effective up to a price of £200 per person. The new greenway and Active Living by Design programme have higher cost thresholds at £950 and £830 per person, respectively. The highest threshold observed is for Woods In and Around Towns, which was cost-effective up to a cost of £XXX per person. This intervention remained highly cost-effective even when walking activity gains only were evaluated, for which cost-effectiveness was expected up to intervention costs of £XXX. At the other end of the scale are park renovations, which are cost-effective only up to an intervention cost of £20 per person.

953

954

955

956

957

958

959

978
979
980

Table 3.2: Cost-effectiveness results for Cycling Demonstration Towns

	Intervention	Comparator	Incremental
Intervention costs	£11	£0	£10.96
Breast cancer	£731	£730	£0.30
Colon cancer	£175	£175	£0.05
Diabetes	£4,258	£4,259	−£0.24
Stroke	£4,303	£4,301	£1.29
CHD	£2,415	£2,414	£0.50
Total costs	£11,892	£11,879	£12.85


Healthy QALY	16.17	16.17	0.0053
Comorbidity QALY loss	0.87	0.87	0.0001
Net QALYs	15.30	15.29	0.0051

ICER	£2,496
-------------	---------------

Net health benefit	0.005
---------------------------	--------------

981
982
983
984
985

Figure 3.8: Cost-effectiveness of Cycling Demonstration Towns by intervention cost



986
987
988
989

990
991
992

Table 3.3: Cost-effectiveness results for Smarter Choices, Smarter Places

	Intervention	Comparator	Incremental
Intervention costs	£91	£0	£90.95
Breast cancer	£732	£730	£1.33
Colon cancer	£175	£175	£0.20
Diabetes	£4,258	£4,259	−£1.02
Stroke	£4,307	£4,301	£5.70
CHD	£2,417	£2,414	£2.20
Total costs	£11,979	£11,879	£99.37


Healthy QALY	16.19	16.17	0.0230
Comorbidity QALY loss	0.88	0.87	0.0006
Net QALYs	15.32	15.29	0.0225

ICER	£4,423
-------------	---------------

Net health benefit	0.017
---------------------------	--------------

993
994
995
996
997
998


Figure 3.9: Cost-effectiveness of Smarter Choices, Smarter Places by intervention cost



999
1000
1001
1002
1003
1004

1005
1006
1007

Figure 3.10: Cost-effectiveness of Fitter for Walking by intervention cost



1008
1009
1010
1011

1012 **Table 3.4: Cost-effectiveness results for park renovations**

1013

	Intervention	Comparator	Incremental
Intervention costs	£212	£0	£211.98
Breast cancer	£731	£730	£0.06
Colon cancer	£175	£175	£0.01
Diabetes	£4,259	£4,259	-£0.05
Stroke	£4,302	£4,301	£0.24
CHD	£2,415	£2,414	£0.10
Total costs	£12,092	£11,879	£212.34

Healthy QALY	16.17	16.17	0.0010
Comorbidity QALY loss	0.87	0.87	0.0000
Net QALYs	15.29	15.29	0.0010

ICER	£215,989
-------------	-----------------

Net health benefit	-0.010
---------------------------	---------------

1014


1015

1016

1017

1018

Figure 3.11: Cost-effectiveness of park renovations by intervention cost



1019

1020

1021

1022

1023
1024

Table 3.5: Cost-effectiveness results for Connswater Community Greenway

	Intervention	Comparator	Incremental
Intervention costs	£72	£0	£71.87
Breast cancer	£731	£730	£0.58
Colon cancer	£175	£175	£0.09
Diabetes	£4,258	£4,259	-£0.46
Stroke	£4,304	£4,301	£2.48
CHD	£2,415	£2,414	£0.96
Total costs	£11,955	£11,879	£75.52


Healthy QALY	16.18	16.17	0.0101
Comorbidity QALY loss	0.87	0.87	0.0002
Net QALYs	15.30	15.29	0.0099

ICER	£7,652
-------------	---------------

Net health benefit	0.006
---------------------------	--------------

1025
1026
1027
1028
1029
1030

Figure 3.12: Cost-effectiveness of Connswater Community Greenway by intervention cost



1031
1032
1033

1034 **Figure 3.13: Cost-effectiveness of unspecified new greenway by intervention cost**

1035



1036

1037

1038

1039
1040
1041

Table 3.6: Cost-effectiveness results for Active Living by Design

	Intervention	Comparator	Incremental
Intervention costs	£43	£0	£42.99
Breast cancer	£733	£730	£2.52
Colon cancer	£175	£175	£0.38
Diabetes	£4,257	£4,259	-£1.85
Stroke	£4,312	£4,301	£10.91
CHD	£2,419	£2,414	£4.20
Total costs	£11,939	£11,879	£59.16

Healthy QALY	16.21	16.17	0.0434
Comorbidity QALY loss	0.88	0.87	0.0011
Net QALYs	15.34	15.29	0.0424

ICER	£1,397
-------------	---------------

Net health benefit	0.039
---------------------------	--------------

1042
1043
1044
1045
1046

Figure 3.14: Cost-effectiveness of Active Living by Design by intervention cost



1047
1048
1049
1050

1051 **Table 3.7: Cost-effectiveness results for Woods In and About Towns (full activity**
 1052 **gain)**

1053

	Intervention	Comparator	Incremental
Intervention costs	£XXX	£0	£XXX
Breast cancer	£XXX	£730	£XXX
Colon cancer	£XXX	£175	£XXX
Diabetes	£XXX	£4,259	£XXX
Stroke	£XXX	£4,301	£XXX
CHD	£XXX	£2,414	£XXX
Total costs	£XXX	£11,879	£XXX
QALYs	£XXX	16.17	£XXX
QAYLL	£XXX	0.87	£XXX
Net QALYs	£XXX	15.29	£XXX
ICER			£XXX
Net health benefit			£XXX

1054

1055

1056

1057 **Table 3.8: Cost-effectiveness results for Woods In and About Towns (walking**
 1058 **activity gain only)**

1058

1059


	Intervention	Comparator	Incremental
Intervention costs	£XXX	£0	£XXX
Breast cancer	£XXX	£730	£XXX
Colon cancer	£XXX	£175	£XXX
Diabetes	£XXX	£4,259	£XXX
Stroke	£XXX	£4,301	£XXX
CHD	£XXX	£2,414	£XXX
Total costs	£XXX	£11,879	£XXX
QALYs	£XXX	16.17	£XXX
QAYLL	£XXX	0.87	£XXX
Net QALYs	£XXX	15.29	£XXX
ICER			£XXX
Net health benefit			£XXX

1060

1061

1062
1063
1064

Figure 3.15: Cost-effectiveness of Woods In and About Towns by intervention cost



1065

1066 3.3 SENSITIVITY ANALYSIS

1067

1068 To ascertain the robustness of the results, we performed univariate sensitivity analysis of 32
1069 separate parameters contained in the model. The base case assumed a τ value of 0 and that
1070 there was no decay of effect. This involves each selected parameter being varied in isolation
1071 to assess its impact on the model's results. We summarise these results in a series of tornado
1072 diagrams that plot many univariate sensitivity analyses simultaneously, and allows the key
1073 drivers of the model to be identified as the impact of each parameter can be directly compared
1074 with all the others. For each parameter, a high and low value replace the base case value
1075 and the difference in NHB is shown.

1076

1077 The amount by which the parameter was varied for the high and low values depended upon
1078 the data we had. For parameters where uncertainty was quantified by a standard error or
1079 confidence interval (effect of MET on risk and HRQOL), we used the upper and low 95%
1080 confidence band values. Thus, parameters which we are more certain of are varied to a lesser
1081 degree, reducing its relative impact on NHB. For parameters where this information was not
1082 available, the base case values were adjusted by a factor of 20%.

1083

1084 Two tornado diagrams for the general population are shown in Figure 3.16 and Figure 3.17.
1085 These represent pessimistic and optimistic scenarios, respectively. The pessimistic scenario
1086 uses an intervention costing £100 per person and generating a mean increase of 10 MET
1087 minutes per week. The optimistic scenario intervention costs £25 per person and increases
1088 MET minutes per week by 50. The analyses are run over a lifetime time with zero decay and
1089 cost-effectiveness threshold of £20,000 per QALY.

1090

1091 The tornado diagrams show that a highly influential parameter is the effect of MET minutes
1092 per week on mortality risk for females over 65. The same parameter for males and the mean
1093 increase in MET minutes per week are also key drivers of NHB. Intervention cost, meanwhile,
1094 was influential in the pessimistic scenario only. In these comparisons, none of the parameters
1095 have enough of an impact to change the direction of results within the range varied. Co-
1096 morbidity costs and disutilities had virtually no impact on the result. However, the relationship
1097 between comorbidity risk and physical activity did have a small influence on NHB. Of the
1098 comorbidities, stroke was the most important.


1099

1100 Figure 3.18 and Figure 3.19 show the tornado diagrams when the pessimistic and optimistic
1101 scenarios, respectively, are run for the limited mobility population. In both cases, the
1102 comorbidity costs and disutilities are again largely inconsequential. When MET gain is low and
1103 intervention cost is high (Figure 3.18), the effect of MET on mortality for females over 65 is
1104 still the most influential parameter. However, intervention cost and the effect of MET on utility
1105 score take on a greater role in determining the net health benefit compared to when analyzing
1106 the general population. In the optimistic scenario (Figure 3.19), the influence of intervention
1107 cost is again far less. A direct comparison with the general population in Figure 3.17 again
1108 demonstrates how for the limited mobility population, the impact of MET minutes per week on
1109 utility score is a greater driver of the results.

1110

1111
 1112
 1113


Figure 3.16: Tornado diagram (10 MET minutes per week increase, £100 per person intervention cost, general population) – pessimistic scenario



1114
 1115

1116
 1117
 1118


Figure 3.17: Tornado diagram (50 MET minutes per week increase, £25 per person intervention cost, general population) – optimistic scenario



1119
 1120
 1121
 1122

1123
1124
1125


Figure 3.18: Tornado diagram (10 MET minutes per week increase, £100 per person intervention cost, limited mobility population) – pessimistic scenario



1126
1127
1128

1129
 1130
 1131

Figure 3.19: Tornado diagram (50 MET minutes per week increase, £25 per person intervention cost, limited mobility population) – optimistic scenario



1132
 1133
 1134
 1135

Section 4: Discussion

1136

1137

1138

1139

1140 This economic evaluation can be used to demonstrate the likely cost-effectiveness of an
1141 environmental intervention designed to improve physical activity, given its effectiveness at
1142 improving physical activity and the per person cost. Scenario analyses show, for a given
1143 range of intervention costs, what improvements in physical activity are required for an
1144 intervention to be cost-effective. For interventions costing £25 per person, the increase in MET
1145 minutes per week required for cost-effectiveness is 5.5, i.e. the equivalent of 2.5% of the
1146 population cycling an additional 30 minutes per week. On the other hand, an intervention
1147 costing £250 per person would require mean MET minutes per week to increase by 39 in order
1148 to be cost-effective. This is equivalent to 26% of the population cycling an extra 30 minutes
1149 per week. However, these are dependent upon two central assumptions underpinning the
1150 base case analysis: (i) activity gains are maintained through the life course and (ii)
1151 interventions do not impose any annual maintenance costs. Assuming an instantaneous 50%
1152 decay on activity gains was associated with 98% increase in the minimum MET minutes per
1153 week required for cost-effectiveness. The increase was 84% when we assumed that annual
1154 maintenance costs were 5% of the initial intervention cost.

1155

1156 The scope of environmental interventions that are covered by the guidance is broad, and the
1157 cost-effectiveness of any intervention may depend on how and to whom they are delivered.
1158 For example, cycling lanes may generate long-term increases in physical activity if it is placed
1159 in an area with little existing infrastructure, but only short-term increases if it is a novel addition
1160 to multiple existing routes. Similarly, constructing a park may affect the less or more active
1161 individuals depending on how active the neighbouring populace is. Our results indicate that
1162 the distribution of physical activity gains is not a strong determinant of cost-effectiveness.
1163 However, the ability of the intervention to sustain activity in the long-term is much more so,
1164 particularly when the intervention cost is higher. Another factor not considered in this analysis
1165 is the cost of maintaining improvements to the built and natural environment, such as
1166 resurfacing paths or pruning trees and bushes. Whilst these are likely to have small per person
1167 costs when spread over a population, their inclusion will reduce the cost-effectiveness of an
1168 intervention.

1169

1170 Our analysis also showed how smaller MET gains are required for interventions to be cost-
1171 effective for limited mobility populations. Driving these results are the lower baseline physical
1172 activity levels of this population, which mean that any increases in physical activity create
1173 greater relative comorbidity and mortality risk reductions and larger health gains. However,
1174 caution should be taken when interpreting the cost-effectiveness results for this subpopulation,
1175 since the benefits of the environmental interventions that this guidance concerns will not tend
1176 to be solely concentrated amongst those with limited mobility. The costs and benefits will, in
1177 reality, be shared with general population; their inclusion will change the cost-effectiveness.

1178

1179 The case study results show that three of the main intervention themes (changes to transport
1180 infrastructure, public transport frequency and access and open space access and street

1181 design) can be highly cost-effective ways of increasing physical activity and improving health.
1182 The scheme for increasing public transport frequency and access, Smarter Choices, Smarter
1183 Places, performed particularly well and would be cost-effective up to an intervention cost of
1184 around £440 per person (£22,000,000 for a population of 50,000 people). The least cost-
1185 effective intervention was found for park renovation, which was cost-effective up to an
1186 intervention cost of £25 per person. Such an estimate however, depends largely upon the
1187 facilities available in the park.

1188
1189 It is important to note that, in our case studies, the per person net health benefits that we report
1190 relate strictly to the populations defined in the intervention. For the three larger,
1191 multicomponent interventions (Cycling Demonstration Towns, Smarter Choices, Smarter
1192 Places and Active Living By Design), our results are representative of larger populations more
1193 akin to those considered by decision-makers. However, much more caution should be taken
1194 when interpreting the results of park renovation, new greenway, the Connswater Community
1195 Greenway project and the Woods In and Around Town. This is because the study populations
1196 are limited to within a short distance of where the intervention takes place. Although expanding
1197 the population size (to reflect the whole local authority, for instance) will also reduce the
1198 average cost of these interventions, we would also expect average activity gain to fall, as those
1199 further away from the intervention are less likely to benefit. Therefore, the impact of this
1200 limitation will depend on how much of the population relevant to the decision-maker is included
1201 in the study population.

1202
1203 Sensitivity analyses investigated the robustness of the results to changes in specific parameter
1204 values. Of the 32 we analysed, the effect of physical activity on the mortality risk of women
1205 over 65 was a consistently influential parameter on NHB, regardless of the intervention
1206 characteristics or the target population. This is likely a combination of two factors: first, the
1207 absolute effect of activity for this subgroup on relative risk was much larger than for any other,
1208 and covered the age group in which risk was at its highest. The second factor is the uncertainty
1209 around this and the other parameters extracted from the Anderson *et al.* study. The 95%
1210 confidence interval for the parameter of interest had a range of 0.064, compared to a range of
1211 0.01 for the effect of activity on stroke risk, which was extracted, conversely, from a large
1212 meta-analysis. Also noteworthy was the greater influence of the effect of activity on HRQOL
1213 for limited mobility populations. This is likely explained by the lower baseline physical activity
1214 levels of this group, which mean that increases in activity generate relatively more health
1215 benefits.

1216
1217 A number of simplifying assumptions were required to undertake the analysis; the following
1218 section will explore their potential impacts on our results.

1219
1220 A critical assumption that underpins all of our results is the reliability of the physical activity
1221 distributions observed in the 2014 Health Survey for England as being representative of the
1222 general and limited mobility populations. Given that survey weights could not be used to adjust
1223 the observations in this stage of the analysis, selection bias could be factor if, for example, the
1224 less active are less likely to participate in the survey. This could have the potential impact of
1225 the average activity levels being overestimated and NHB underestimated.

1226

1227 The temporal effects of physical activity are also simplified in the model. Risk reductions occur
1228 instantaneously for both mortality and comorbidities, whereas in reality these benefits will likely
1229 be transferred incrementally. This would cause NHB to be overestimated since the health
1230 benefits of extra activity are overestimated. Similarly, when activity improvements are
1231 expected to decay, affected individuals will do so immediately and entirely. This would have
1232 the opposite effect of underestimating NHB since the small risk reductions in the decaying
1233 period are removed. However, we would expect that both of these effects to be small given
1234 the small absolute changes to the relative risks that even large improvements in MET minutes
1235 per week endows.

1236
1237 The use of a continuous treatment effect (increase in MET minutes per week) placed greater
1238 restrictions on evidence that could be integrated into the model, since multiple data points (i.e.
1239 activity level thresholds) were required in order to fit continuous relative risk functions. This
1240 meant that, of the large number of comorbidities that are associated with physical activity, only
1241 five were explicitly modelled in the analysis. This was potentially offset by estimating HRQOL
1242 as a function of physical activity level, since some of the impact of activity on comorbidities
1243 (and thereby HRQOL) was incorporated into the utility scores without being explicitly modelled.
1244 Any impact not captured, however, would mean that the net health benefits presented in this
1245 analysis are underestimated.

1246
1247 The estimation of the physical activity gains and costs associated with the case study
1248 interventions also presents a further limitation. Two of the studies examined calculated activity
1249 gains by the observation or surveying of service users. This would invariably lead to higher
1250 estimates of activity as it precludes people not regularly using the service, who it may be
1251 assumed are less active.

1252
1253 Lastly, there are a number of intervention effects that are not captured in the model. An
1254 example of health benefits not incorporated in the model is the reduction in comorbidities
1255 associated with the reduction in vehicle use, which in turn will reduce air pollution. Similarly,
1256 physical activity gains may involve switching from driving to cycling, which will have a net effect
1257 on an individual's mortality risk: these effects are not accounted by the model either. We also
1258 do not include the potential benefits of preventing disease in individuals who are productive
1259 members of society. Whilst this may be of interest to decision-makers, a consistent analysis
1260 would have to take into account how removing funding from other health-improving
1261 programmes to finance a new intervention will reduce productivity. Currently, no such analyses
1262 have been conducted.

1263
1264 Given the importance of physical activity in improving health and the importance of the natural
1265 and built environment in influencing activity levels, the analysis presented here provides
1266 valuable information on the relationship between the cost-effectiveness of potential
1267 interventions and their characteristics, namely their cost and the physical activity
1268 improvements they generate.

References

1269

1270

- 1271 1. gov.co.uk. Start active, stay active: report on physical activity in the UK. London: 2011.
1272 Available from: [https://www.gov.uk/government/publications/start-active-stay-active-a-report-](https://www.gov.uk/government/publications/start-active-stay-active-a-report-on-physical-activity-from-the-four-home-countries-chief-medical-officers)
1273 [on-physical-activity-from-the-four-home-countries-chief-medical-officers](https://www.gov.uk/government/publications/start-active-stay-active-a-report-on-physical-activity-from-the-four-home-countries-chief-medical-officers).
1274 2. World Health Organisation (WHO). Global Recommendations on Physical Activity for
1275 Health. Switzerland: World Health Organisation (WHO); 10th March 2010. Available from:
1276 http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf.
1277 3. Varley J B, M, Aaltonen G,. Everybody active, every day: The case for taking action now.
1278 London: England PH; 2014. Available from:
1279 [https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/366522/14102](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/366522/14102_2_EAED_MP_toolkit.pdf)
1280 [2_EAED_MP_toolkit.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/366522/14102_2_EAED_MP_toolkit.pdf).
1281 4. Allender S, Foster C, Scarborough P, Rayner M. The burden of physical activity-related ill
1282 health in the UK. *J Epidemiol Community Health*. 2007;61(4):344-8.
1283 5. National Institute for Health and Care Excellence (NICE). Developing NICE Guidelines: The
1284 Manual. London: October 2014. Available from:
1285 [https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf)
1286 [guidelines-the-manual.pdf](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf).
1287 6. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr., Tudor-Locke C, *et*
1288 *al.* 2011 Compendium of Physical Activities: a second update of codes and MET values. *Med*
1289 *Sci Sports Exerc*. 2011;43(8):1575-81.
1290 7. World Health Organisation (WHO). What is Moderate-intensity and Vigorous-intensity
1291 Physical Activity? World Health Organisation (WHO);, 2017. [cited 10th March 2017]. Available
1292 from: http://www.who.int/dietphysicalactivity/physical_activity_intensity/en/.
1293 8. Minton J, Dimairo M, Everson-Hock E, Scott E, Goyder E. Exploring the relationship
1294 between baseline physical activity levels and mortality reduction associated with increases in
1295 physical activity: a modelling study. *BMJ Open*. 2013;3(10):e003509.
1296 9. Sloman L, Cavill N, Cope A, Muller L, A K. Analysis and synthesis of evidence on the effects
1297 of investment in six Cycling Demonstration Towns 2009. Available from:
1298 [http://www.transportforqualityoflife.com/u/files/Analysis%20and%20Synthesis%20Nov%2020](http://www.transportforqualityoflife.com/u/files/Analysis%20and%20Synthesis%20Nov%202009.pdf)
1299 [09.pdf](http://www.transportforqualityoflife.com/u/files/Analysis%20and%20Synthesis%20Nov%202009.pdf).
1300 10. Norwood P, Eberth B, Farrar S, Anable J, Ludbrook A. Active travel intervention and
1301 physical activity behaviour: an evaluation. *Soc Sci Med*. 2014;113:50-8.
1302 11. Adams EJ, Cavill N. Engaging communities in changing the environment to promote
1303 transport-related walking: Evaluation of route use in the 'Fitter for Walking' project. *Journal of*
1304 *Transport & Health*. 2015;2(4):580-94.
1305 12. Cohen DA, Han B, Isacoff J, Shulaker B, Williamson S, Marsh T, *et al.* Impact of park
1306 renovations on park use and park-based physical activity. *J Phys Act Health*. 2015;12(2):289-
1307 95.
1308 13. Dallat MA, Soerjomataram I, Hunter RF, Tully MA, Cairns KJ, Kee F. Urban greenways
1309 have the potential to increase physical activity levels cost-effectively. *Eur J Public Health*.
1310 2014;24(2):190-5.
1311 14. West ST, Shores KA. The Impacts of Building a Greenway on Proximate Residents'
1312 Physical Activity. *Journal of Physical Activity and Health*. 2011;8(8):1092-97.
1313 15. Chomitz VR, McDonald JC, Aske DB, Arsenault LN, Riales NA, Brukilacchio LB, *et al.*
1314 Evaluation results from an active living intervention in Somerville, Massachusetts. *Am J Prev*
1315 *Med*. 2012;43(5 Suppl 4):S367-78.
1316 16. Department of Health. Programme Budgeting Aggregate PCT Expenditure for all
1317 programmes and subcategories for financial years 2003/04 to 2012/13. In: Health Do, editor.
1318 London; 2017.
1319 17. Personal Social Services Research Unit (PSSRU). Unit Costs of Health & Social Care
1320 2016. Canterbury: PSSRU; 2016. Available from: [http://www.pssru.ac.uk/project-pages/unit-](http://www.pssru.ac.uk/project-pages/unit-costs/2016/)
1321 [costs/2016/](http://www.pssru.ac.uk/project-pages/unit-costs/2016/).

- 1322 18. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, *et al.* Cancer prevalence
1323 in the United Kingdom: estimates for 2008. *Br J Cancer*. 2009;101(3):541-7.
- 1324 19. Trueman, *et al.* Bowel Cancer Services: Costs and Benefits York: 2007. Available from:
1325 [https://www.sheffield.ac.uk/polopoly_fs/1.44049!/file/FinalBowelCancerSummaryReport-](https://www.sheffield.ac.uk/polopoly_fs/1.44049!/file/FinalBowelCancerSummaryReport-Apr07.pdf)
1326 [Apr07.pdf](https://www.sheffield.ac.uk/polopoly_fs/1.44049!/file/FinalBowelCancerSummaryReport-Apr07.pdf).
- 1327 20. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of
1328 Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and
1329 productivity costs. *Diabet Med*. 2012;29(7):855-62.
- 1330 21. England PH. Diabetes prevalence model for local authorities and CCGs. Public Health
1331 England; 2016. [cited 13th March 2017]. Available from:
1332 <http://www.yhpho.org.uk/resource/view.aspx?RID=154049>.
- 1333 22. (NICE) NifHaCE. Venous thromboembolism: reducing the risk for patients in hospital
1334 (CG92). London: 2010. Available from:
1335 [https://www.nice.org.uk/guidance/cg92/resources/venous-thromboembolism-reducing-the-](https://www.nice.org.uk/guidance/cg92/resources/venous-thromboembolism-reducing-the-risk-for-patients-in-hospital-975745995973)
1336 [risk-for-patients-in-hospital-975745995973](https://www.nice.org.uk/guidance/cg92/resources/venous-thromboembolism-reducing-the-risk-for-patients-in-hospital-975745995973).
- 1337 23. British Heart Foundation B. Cardiovascular Disease Statistics 2015. London: 2015.
1338 Available from: <https://www.bhf.org.uk/publications/statistics/cvd-stats-2015>.
- 1339 24. Hall PS, Hamilton P, Hulme CT, Meads DM, Jones H, Newsham A, *et al.* Costs of cancer
1340 care for use in economic evaluation: a UK analysis of patient-level routine health system data.
1341 *Br J Cancer*. 2015;112(5):948-56.
- 1342 25. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-
1343 based health status measure in adults with Type 2 diabetes mellitus. *Diabet Med*.
1344 2011;28(4):395-413.
- 1345 26. Golicki D, Niewada M, Buczek J, Karlinska A, Kobayashi A, Janssen MF, *et al.* Validity of
1346 EQ-5D-5L in stroke. *Qual Life Res*. 2015;24(4):845-50.
- 1347 27. Stevanovic J, Pechlivanoglou P, Kampinga MA, Krabbe PF, Postma MJ. Multivariate Meta-
1348 Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease. *PLoS One*.
1349 2016;11(3):e0152030.
- 1350 28. Office for National Statistics. National Life Tables: England. In: Statistics OfN, editor.;
1351 2016.
- 1352 29. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. *Economics CfH*; 1999.
1353 Available from: <https://www.york.ac.uk/che/pdf/DP172.pdf>.
- 1354 30. UK D. DIABETES IN THE UK 2012, Key statistics on diabetes. 2012. Available from:
1355 <https://www.diabetes.org.uk/diabetes-in-the-uk-2012>.
- 1356 31. Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology
1357 of cardiovascular disease in the UK 2014. *Heart*. 2015;101(15):1182-9.
- 1358 32. Liu JLY. The economic burden of coronary heart disease in the UK. *Heart*. 2002;88(6):597-
1359 603.
- 1360 33. Cancer Research UK. Breast cancer in men. London: Cancer Research UK; 2014. [cited
1361 13th March 2017]. Available from: [http://www.cancerresearchuk.org/about-cancer/type/rare-](http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/breast-cancer-in-men)
1362 [cancers/rare-cancers-name/breast-cancer-in-men](http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/breast-cancer-in-men).
- 1363 34. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, *et al.* Physical
1364 activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and
1365 ischemic stroke events: systematic review and dose-response meta-analysis for the Global
1366 Burden of Disease Study 2013. *BMJ*. 2016;354:i3857.
- 1367 35. Andersen L, Schnohr P, Schroll M, Hein H. All-cause mortality associated with physical
1368 activity during leisure time, work, sports, and cycling to work. *Archives of Internal Medicine*.
1369 2000;160(11):1621-28.
- 1370 36. Brennan A *ea.* National Institute for Health and Clinical Excellence Public Health
1371 Programme
1372 Walking and cycling: local measures to promote walking and cycling as forms of travel or
1373 recreation: Health economic and modelling report. Sheffield: Research SoHaR; 2012.
1374 Available from: [https://www.nice.org.uk/guidance/ph41/evidence/economic-modelling-report-](https://www.nice.org.uk/guidance/ph41/evidence/economic-modelling-report-430262893)
1375 [430262893](https://www.nice.org.uk/guidance/ph41/evidence/economic-modelling-report-430262893).

- 1376 37. Sustrans. Cycle Path Surface Options. Technical Information Note No. 8. Bristol: 2012.
1377 Available from: [http://www.sustrans.org.uk/sites/default/files/images/files/migrated-
1379 pdfs/Technical%20Note%208%20-%20Path%20surfaces\(1\).pdf](http://www.sustrans.org.uk/sites/default/files/images/files/migrated-
1378 pdfs/Technical%20Note%208%20-%20Path%20surfaces(1).pdf).
1380 38. Office NA. Maintaining strategic infrastructure: roads. Office NA; 2014. Available from:
1381 [https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwicqaK2x6nVAhVSaVAKHcoTBQIQFggmMAA&url=https%3A%2F%2Fwww.na
o.org.uk%2Fwp-content%2Fuploads%2F2015%2F06%2FMaintaining-Strategic-
Infrastructure-Roads.pdf&usq=AFQjCNFxGK1hvj5YesavN2vsEkr9TSIPSA](https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwicqaK2x6nVAhVSaVAKHcoTBQIQFggmMAA&url=https%3A%2F%2Fwww.na
1382 o.org.uk%2Fwp-content%2Fuploads%2F2015%2F06%2FMaintaining-Strategic-
1383 Infrastructure-Roads.pdf&usq=AFQjCNFxGK1hvj5YesavN2vsEkr9TSIPSA).
1384